Patents Assigned to CVRx, Inc.
  • Patent number: 10350406
    Abstract: Devices and methods of use for introduction and implantation of an electrode as part of a minimally invasive technique. An implantable baroreflex activation system includes a control system having an implantable housing, an electrical lead, attachable to the control system, and an electrode structure. The electrode structure is near one end of the electrical lead, and includes a monopolar electrode, a backing material having an effective surface area larger than the electrode, and a releasable pivotable interface to mate with an implant tool. The electrode is configured for implantation on an outer surface of a blood vessel and the control system is programmed to deliver a baroreflex therapy via the monopolar electrode to a baroreceptor within a wall of the blood vessel.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: July 16, 2019
    Assignee: CVRx, Inc.
    Inventors: Adam Cates, Eric Lovett, Loren Murney, Kip Ludwig, Paul Pignato, Brian Soltis
  • Patent number: 9511218
    Abstract: Devices and methods of use for introduction and implantation of an electrode as part of a minimally invasive technique. An implantable baroreflex activation system includes a control system having an implantable housing, an electrical lead, attachable to the control system, and an electrode structure. The electrode structure is near one end of the electrical lead, and includes a monopolar electrode, a backing material having an effective surface area larger than the electrode, and a releasable pivotable interface to mate with an implant tool. The electrode is configured for implantation on an outer surface of a blood vessel and the control system is programmed to deliver a baroreflex therapy via the monopolar electrode to a baroreceptor within a wall of the blood vessel.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: December 6, 2016
    Assignee: CVRx, Inc.
    Inventors: Adam Cates, Eric Lovett, Loren Murney, Kip Ludwig, Paul Pignato, Brian Soltis
  • Patent number: 9457189
    Abstract: An implantable baroreflex activation device administers a special electrotherapy program that causes the device to apply electrotherapy to limit a rate of change of blood pressure increase associated with a blood pressure surge event such as a morning blood pressure surge (MBPS).
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: October 4, 2016
    Assignee: CVRx, Inc.
    Inventor: Martin A. Rossing
  • Patent number: 9427583
    Abstract: Devices, systems and methods are described by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably reduced by activating baroreceptors. A baroreceptor activation device is positioned near a baroreceptor, preferably a baroreceptor located in the carotid sinus. A control system may be used to modulate the baroreceptor activation device. The control system may utilize an algorithm defining a stimulus regimen which promotes long term efficacy and reduces power requirements/consumption. The baroreceptor activation device may utilize electrodes to activate the baroreceptors. The electrodes may be adapted for connection to the carotid arteries at or near the carotid sinus, and may be designed to minimize extraneous tissue stimulation.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: August 30, 2016
    Assignee: CVRx, Inc.
    Inventors: Stephen L. Bolea, Robert S. Kieval, Bruce J. Persson, David J. Serdar, Peter T. Keith, Eric D. Irwin, Martin A. Rossing
  • Patent number: 9414760
    Abstract: Physiological parameters of a patient can be used to monitor patient status and/or in conjunction with patient therapy. Physiological cycles may be monitored by implanting a monitoring system into the patient, the system including an implantable pulse generator operably connected to a lead implanted on a carotid sinus of the patient, measuring at least one signal indicative of a physiological parameter of the patient along at least two vectors selected from: a first vector defined between a first electrode of the lead and a second electrode of the lead, a second vector defined between the first electrode of the lead and an electrode integrated into an implantable pulse generator, and a third vector defined between the second electrode of the lead and the electrode integrated into the implantable pulse generator, and providing an output indicative of the at least one signal indicative of the physiological parameter.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: August 16, 2016
    Assignee: CVRx, Inc.
    Inventor: Robert S. Kieval
  • Patent number: 9345877
    Abstract: Embodiments of the present invention generally pertain to devices and methods for use in conjunction with implanting a baroreflex therapy system which includes an implantable pulse generator and associated circuitry contained within a hermetically sealed housing, an elongate flexible electrical lead connectable to the housing, and a monopolar electrode structure coupled with the electrical lead. More specifically, the devices and methods of the present invention allow for a mapping procedure to be conducted as part of the implant procedure prior to fully implanting the baroreflex therapy system.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: May 24, 2016
    Assignee: CVRx, Inc.
    Inventors: Paul Pignato, Vance Kesler, Adam Cates, Bart Carey, Greg Sundberg, Joe DuPay, Luis Miguel Rodriguez
  • Patent number: 9199082
    Abstract: Devices and methods are provided for selecting a location to implant an electrode as part of a baroreflex activation therapy system. Images of a target blood vessel may be obtained with an imaging device, and the image used as part of or in conjunction with a patient-response-mapping procedure to determine a favorable location on the blood vessel to implant the electrode. Alternately, temperature measurements may be taken of a target vessel and utilized as part of or in conjunction with a patient-response-mapping procedure to determine a favorable location on the blood vessel to implant the electrode.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: December 1, 2015
    Assignee: CVRx, Inc.
    Inventors: Nadim Yared, Robert S. Kieval, Adam Cates
  • Patent number: 9044609
    Abstract: Devices, systems and methods are described by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably reduced by activating baroreceptors. A baroreceptor activation device is positioned near a baroreceptor, preferably a baroreceptor located in the carotid sinus. A control system may be used to modulate the baroreceptor activation device. The control system may utilize an algorithm defining a stimulus regimen which promotes long term efficacy and reduces power requirements/consumption. The baroreceptor activation device may utilize electrodes to activate the baroreceptors. The electrodes may be adapted for connection to the carotid arteries at or near the carotid sinus, and may be designed to minimize extraneous tissue stimulation.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: June 2, 2015
    Assignee: CVRx, Inc.
    Inventors: Stephen L. Bolea, Robert S. Kieval, Bruce J. Persson, David J. Serdar, Peter T. Keith, Eric D. Irwin, Martin A. Rossing
  • Patent number: 9026215
    Abstract: An implantable baroreflex activation device administers a special electrotherapy program that causes the device to apply electrotherapy to limit a rate of change of blood pressure increase associated with a blood pressure surge event such as a morning blood pressure surge (MBPS).
    Type: Grant
    Filed: December 29, 2005
    Date of Patent: May 5, 2015
    Assignee: CVRx, Inc.
    Inventor: Martin A. Rossing
  • Patent number: 8977359
    Abstract: A real time, heart rate monitor and a hemodynamic monitoring system are operably integrated with the programmer system for an implantable hypertension treatment device. A series of tests are automatically performed to set programmable parameters for the implantable hypertension treatment device without clinician intervention. In one embodiment, a predetermined level of a dose-response evaluation is initiated for each test in the series. Preferably, the programmer system monitors the heart rate to determine whether a hemodynamic measurement should be initiated at all for a given test, as well as whether the hemodynamic measurement should be initiated earlier or later than a predetermined settling period for assessing the sympathetic nervous response to the test dose. In one embodiment, this determination is based on heart rate stability/instability.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: March 10, 2015
    Assignee: CVRx, Inc.
    Inventor: Martin A. Rossing
  • Patent number: 8948874
    Abstract: Devices and methods of use are described for identification, treatment, and/or management of heart failure and/or associated conditions. An exemplary device may include a first fluid status monitoring circuit configured to monitor a first fluid status indicator of a pulmonary fluid status associated with pulmonary edema, a second fluid status monitoring circuit configured to monitor a separate and different second fluid status indicator of a non-pulmonary fluid status, and a controller coupled to the first and second fluid status monitoring circuits, and a therapy circuit coupled to the controller. The controller is configured to use information about the first and second fluid status indicators to determine a therapy control signal to control a therapy, and the therapy circuit is configured to provide therapy in response to the therapy control signal to adjust at least one of the pulmonary fluid status or the non-pulmonary fluid status.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: February 3, 2015
    Assignee: CVRx, Inc.
    Inventors: Dimitrios Georgakopoulos, Eric Grant Lovett
  • Patent number: 8880190
    Abstract: Devices, systems and methods are described by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably reduced by activating baroreceptors. A baroreceptor activation device is positioned near a baroreceptor, preferably a baroreceptor located in the carotid sinus. A control system may be used to modulate the baroreceptor activation device. The control system may utilize an algorithm defining a stimulus regimen which promotes long term efficacy and reduces power requirements/consumption. The baroreceptor activation device may utilize electrodes to activate the baroreceptors. The electrodes may be adapted for connection to the carotid arteries at or near the carotid sinus, and may be designed to minimize extraneous tissue stimulation.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: November 4, 2014
    Assignee: CVRx, Inc.
    Inventors: Robert S Kieval, Peter T Keith, Matthew Burns, Thomas Hektner
  • Patent number: 8838246
    Abstract: Devices, systems and methods are described which control blood pressure, nervous system activity, and neurohormonal activity by activating baroreceptors. By selectively and controllably activating baroreceptors, the present invention reduces excessive blood pressure, sympathetic nervous system activity and neurohormonal activity, thereby minimizing their deleterious effects on a heart, vasculature and other organs and tissues. A baroreceptor activation device is positioned near a low-pressure baroreceptor, preferably in the venous system, heart, or pulmonary vasculature.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: September 16, 2014
    Assignee: CVRx, Inc.
    Inventor: Robert S. Kieval
  • Patent number: 8788066
    Abstract: Devices and methods of use for introduction and implantation of an electrode as part of a minimally invasive technique. An implantable baroreflex activation system includes a control system having an implantable housing, an electrical lead, attachable to the control system, and an electrode structure. The electrode structure is near one end of the electrical lead, and includes a monopolar electrode, a backing material having an effective surface area larger than the electrode, and a releasable pivotable interface to mate with an implant tool. The electrode is configured for implantation on an outer surface of a blood vessel and the control system is programmed to deliver a baroreflex therapy via the monopolar electrode to a baroreceptor within a wall of the blood vessel.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: July 22, 2014
    Assignee: CVRx, Inc.
    Inventors: Adam Cates, Eric Lovett, Loren Murney, Kip Ludwig, Paul Pignato, Brian Soltis
  • Patent number: 8755907
    Abstract: Systems and methods provide baroreflex activation to treat or reduce pain and/or to cause or enhance sedation or sleep. Methods involve activating the baroreflex system to provide pain reduction, sedation, improved sleep or some combination thereof. Systems include at least one baroreflex activation device, at least one sensor for sensing physiological activity of the patient, and a processor coupled with the baroreflex activation device(s) and the sensor(s) for processing sensed data received from the sensor and for activating the baroreflex activation device. In some embodiments, the system is fully implantable within a patient, such as in an intravascular, extravascular or intramural location.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: June 17, 2014
    Assignee: CVRx, Inc.
    Inventors: Robert S. Kieval, Martin A. Rossing
  • Publication number: 20140163649
    Abstract: Devices and methods of use are described for identification, treatment, and/or management of heart failure and/or associated conditions. An exemplary device may include a first fluid status monitoring circuit configured to monitor a first fluid status indicator of a pulmonary fluid status associated with pulmonary edema, a second fluid status monitoring circuit configured to monitor a separate and different second fluid status indicator of a non-pulmonary fluid status, and a controller coupled to the first and second fluid status monitoring circuits, and a therapy circuit coupled to the controller. The controller is configured to use information about the first and second fluid status indicators to determine a therapy control signal to control a therapy, and the therapy circuit is configured to provide therapy in response to the therapy control signal to adjust at least one of the pulmonary fluid status or the non-pulmonary fluid status.
    Type: Application
    Filed: December 27, 2013
    Publication date: June 12, 2014
    Applicant: CVRx, Inc.
    Inventors: Dimitrios Georgakopoulos, Eric Grant Lovett
  • Patent number: 8744586
    Abstract: Devices and methods for use of identification, treatment and/or management of heart failure and/or associated conditions. Methods may include providing a baroreflex therapy system, providing an implantable measurement device proximate a blood vessel of a patient, the implantable measurement device including a plurality of electrodes, determining an impedance of the blood vessel with the implantable measurement device over a time period of at least one cardiac cycle, generating at least one signal representative of a pressure waveform based on the impedance, activating, deactivating or otherwise modulating the baroreflex therapy system to deliver a therapy to treat heart failure based at least in part on the at least one signal representative of the pressure waveform.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: June 3, 2014
    Assignee: CVRx, Inc.
    Inventors: Dimitrios Georgakopoulos, Eric Grant Lovett, Nadim Yared
  • Patent number: 8715327
    Abstract: A system for stimulating a baroreflex of a patient that includes a first light source with a first emitter for emitting a first light, the first emitter at a first location proximate a target tissue having baroreceptor cells, and a second light source including a second emitter and for emitting a second light, the second emitter at a second location proximate the target tissue. The system also includes a control circuit coupled to the first and the second light sources, the control circuit configured to activate the first and the second light sources such that the first light traverses a first pathway to arrive at and penetrate the first portion of the target tissue and the second light-like traverses a second pathway to arrive at and penetrate the second portion of the target tissue, thereby stimulating the baroreceptor cells and activating a baroreflex of the patient.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: May 6, 2014
    Assignee: CVRx, Inc.
    Inventors: Eric G. Lovett, Kip Ludwig
  • Patent number: 8718789
    Abstract: Devices, systems and methods are described by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably reduced by activating baroreceptors. A baroreceptor activation device is positioned near a baroreceptor, preferably a baroreceptor located in the carotid sinus. A control system may be used to modulate the baroreceptor activation device. The control system may utilize an algorithm defining a stimulus regimen which promotes long term efficacy and reduces power requirements/consumption. The baroreceptor activation device may utilize electrodes to activate the baroreceptors. The electrodes may be adapted for connection to the carotid arteries at or near the carotid sinus, and may be designed to minimize extraneous tissue stimulation.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: May 6, 2014
    Assignee: CVRx, Inc.
    Inventors: Stephen L. Bolea, Robert S. Kieval, Bruce J. Persson, David J. Serdar, Peter T. Keith, Eric D. Irwin, Martin A. Rossing
  • Patent number: 8712522
    Abstract: A real time, heart rate monitor and a hemodynamic monitoring system are operably integrated with the programmer system for an implantable hypertension treatment device. A series of tests are automatically performed to set programmable parameters for the implantable hypertension treatment device without clinician intervention. In one embodiment, a predetermined level of a dose-response evaluation is initiated for each test in the series. Preferably, the programmer system monitors the heart rate to determine whether a hemodynamic measurement should be initiated at all for a given test, as well as whether the hemodynamic measurement should be initiated earlier or later than a predetermined settling period for assessing the sympathetic nervous response to the test dose. In one embodiment, this determination is based on heart rate stability/instability.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: April 29, 2014
    Assignee: CVRx, Inc.
    Inventor: Martin A. Rossing